LACUTAMAB IN PATIENTS (PTS) WITH ADVANCED MYCOSIS FUNGOIDES (MF) ACCORDING TO KIR3DL2 EXPRESSION: EARLY RESULTS FROM THE TELLOMAK PHASE 2 TRIAL

Autor:	F. Rotolo, Olivier Dereure, Stéphane Dalle, P. L. Zinzani, Youn H. Kim, Marie Beylot-Barry, H. A Azim, L. Mortier, P L Ortiz-Romero, Martine Bagot, Eric N. Jacobsen, Pierluigi Porcu, A. Cambalia
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty Mycosis fungoides business.industry Hematology General Medicine medicine.disease Early results KIR3DL2 Internal medicine medicine In patient business
Zdroj:	Hematological Oncology. 39
ISSN:	1099-1069 0278-0232
DOI:	10.1002/hon.54_2879
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::07cc6a4584c0678d177e2d27e507f0c8 https://doi.org/10.1002/hon.54_2879 Zobrazit plný text záznamu Plný text